Broadfin Holdings LLC reported 1 positions worth $23.66M for the quarter ended Jun 30, 2026, up 0.6% on the prior quarter. It opened 0 new positions, added to 0, trimmed 1 and exited 0. Its largest holding is Angiodynamics Inc at 100% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ANGO Angiodynamics Inc | -250.8K | -12.1% | $3.26M | 100% |
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANGO Angiodynamics Inc | Healthcare | 1.82M | $23.66M | 100% | -250.8K | -12.1% | Reduced | 4.36% |
Tip. Select a row to see that position’s full history at Broadfin Holdings.
As of its Q2 2026 13F filing, Broadfin Holdings LLC’s five largest positions were Angiodynamics Inc (ANGO) at 100.0% of the reported portfolio.
Broadfin Holdings LLC reported a 13F portfolio worth $23.66M across 1 positions for Q2 2026. That is up 0.6% from the previous quarter.
Its largest sales by value were Angiodynamics Inc ($3.26M). It exited 0 positions entirely.
From the Form 13F-HR reports Broadfin Holdings LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.